PulseAugur
EN
LIVE 14:59:03
中文(ZH) 德国默克宣布将以113亿美元现金收购生命科学工具巨头Bio-Techne

Merck KGaA to acquire Bio-Techne for $11.3 billion

By PulseAugur Editorial · [1 sources] ·

Merck KGaA has agreed to acquire Bio-Techne for approximately $11.3 billion in cash, a deal that represents a 36% premium over Bio-Techne's 30-day volume-weighted average price. This acquisition aims to bolster Merck's life science business by integrating Bio-Techne's expertise in life science tools and analytical technologies. The transaction is expected to be funded through a combination of existing cash and new debt. AI

RANK_REASON Acquisition of a major life science tools company by a large multinational corporation. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Merck KGaA to acquire Bio-Techne for $11.3 billion

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Acquisition of a major life science tools company by a large multinational corporation. [lever_c_demoted from significant: ic=1 ai=0.0]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
104 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Germany's Merck Announces $11.3 Billion Cash Acquisition of Life Science Tools Giant Bio-Techne

    6月25日，德国默克集团与美国Bio-Techne公司宣布达成最终收购协议。根据协议，默克将以每股73美元的现金价格收购Bio-Techne，总企业价值约为113亿美元（约合99亿欧元）。该收购价格较Bio-Techne过去一个月的成交量加权平均交易价格溢价36%。Bio-Techne总部位于美国明尼阿波利斯，是一家全球领先的生命科学工具、分析技术及耗材供应商。默克表示，此次收购将通过现有现金和发行新债相结合的方式提供资金。（界面）

RELATED ENTITIES

RELATED TOPICS